Silo Pharma, Inc. (SILO) · Nov 6, 2026 · Share issuance
$850K private placement — $815K net proceeds; 566,666 shares and pre-funded warrant shares
Silo Pharma closed a private placement for roughly $850K gross proceeds, extending liquidity while adding meaningful share dilution and resale overhang.
Silo Pharma is a development-stage biotech funding CNS, psychiatric and chronic-pain programs while also expanding into AI software; its latest 10-Q showed $3.3 million of cash, $2.0 million of short-term investments, a $2.5 million six-month net loss and $1.6 million of operating cash burn. The financing improves near-term liquidity, but it is not a business milestone. Silo closed the private placement on November 6, 2026, raising approximately $850,000 before fees and retaining about $815,000 net for working capital and general corporate purposes. 〔0〕 That gives the company more room to fund operations, but it does not advance a clinical program, add revenue or change the underlying development story.
| Metric | Current deal | Comparison |
|---|---|---|
| Net proceeds (8-K) | $815,000 | — |
| Common shares issued (8-K) | 136,005 | — |
| Pre-funded warrant shares (8-K) | 430,661 | — |
| Total potential shares (8-K) | 566,666 | 1,588,250 outstanding (10-Q cover) |
| Potential increase to recent share count | 35.7% | — |
The cost of the cash is heavy dilution. The deal issued 136,005 common shares and pre-funded warrants for another 430,661 shares—566,666 potential shares in total, or roughly 36% of the 1.588 million shares outstanding reported as of August 13, 2026. The warrants are immediately exercisable for a nominal $0.0001 per share. Economically, that makes most of the financing close to common equity even though much of it is labeled as pre-funded warrants.
The terms point to future resale supply, not new strategic backing. Silo must file a resale registration statement within 30 days and target effectiveness within 60 days, while the purchasers retain broad rights to resell the securities. The financing was therefore a straightforward liquidity raise rather than evidence that investors are funding a newly validated asset or partnership. With the company already reporting enough cash and liquid investments for at least twelve months after its July financing, this raise modestly extends flexibility but also underscores that operating cash needs remain recurring. Bottom line: The deal buys Silo more runway, but it does not change the underlying pipeline story and does so by adding a potentially large block of stock. For the business, that is a mixed financing update leaning slightly negative because the liquidity benefit comes with substantial dilution and no new operating progress.
Resale registration statement due by December 5, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!